Day: March 8, 2022

Intertape Polymer Group Inc. (“IPG”) Enters into Arrangement Agreement to be Acquired by Clearlake Capital Group, L.P. in a US$2.6 Billion Transaction

Written by Customer Service on March 8, 2022. Posted in Public Companies.

IPG shareholders to receive CDN$40.50 per share in cash Transaction provides immediate liquidity and certainty of value to IPG shareholders at a substantial premium of approximately 66% to the 30-day volume weighted average trading priceMONTREAL and SARASOTA, Fla. and SANTA MONICA, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG”, or the “Company”) today announced that it has entered into a definitive agreement to be acquired by an affiliate of Clearlake Capital Group, L.P. (together with certain of its affiliates, “Clearlake”). Under the terms of the agreement, Clearlake will acquire the outstanding shares of IPG for CDN$40.50 per share in an all-cash transaction valued at approximately US$2.6 billion, including net debt. This represents a premium of approximately 82% to the closing price...

Travere Announces Proposed Convertible Senior Notes Offering

Written by Customer Service on March 8, 2022. Posted in Public Companies.

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Notes an option to purchase, for settlement on or before March 31, 2022, up to an additional $37.5 million aggregate principal amount of Notes, solely to cover over-allotments. As described in more detail below, Travere intends to use a portion of the net proceeds from the offering to repurchase a portion of its currently outstanding convertible notes. The Notes will be senior unsecured obligations of Travere and will accrue interest payable semiannually in arrears. The Notes will be convertible...

Xtant Medical Announces Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

BELGRADE, Mont., March 08, 2022 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2021. “Xtant accomplished numerous objectives in 2021 focused on developing new products, expanding our distributor network and growing our adjacent market sales that have us excited about the future of the Company,” said Sean Browne, President and CEO of Xtant Medical. “Our Company achieved year-over-year revenue growth of 4%, and I am particularly pleased with the top-line performance of our biologics business, which grew 8% annually in a very difficult year. As part of our strategic plan, we launched four new products, and we...

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent HighlightsRevenue of $10.1 million for the fourth quarter of 2021 and $34.5 million for the full year of 2021, compared to $3.2 million and $7.7 million, respectively, from the same periods of 2020 U.S. system and rental revenue of $5.0 million for the fourth quarter of 2021, compared to $1.2 million in the prior year period U.S. handpiece and consumables revenue of $3.4 million for the fourth quarter of 2021, compared to $0.8 million in the prior year period Announced positive 5-year WATER Study data on February...

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects XHANCE net revenue for 2022 to be at least $90 million Company expects top-line results from the second of two clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in second quarter 2022 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2021, and provided recent operational highlights. “For the full year of 2021 versus 2020, XHANCE...

Harvard Bioscience Announces Fourth Quarter 2021 Financial Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

Revenue up 7% year-over-year as sales momentum continues, despite global supply chain headwinds Gross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverageHOLLISTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the period ended December 31, 2021. Jim Green, Chairman and CEO said, “The positive trends we reported through the first three quarters of 2021 have carried through with our strong top line performance in Q4. Demand for our pre-clinical products continued to very strong, with revenue up 6% over prior year quarter, and 18% for the full year. Our CMT products also experienced meaningful growth, up 9% over prior year quarter as academic lab sales continue to recover. Operating income for Q4 was...

Nuvei Announces Fourth Quarter and Fiscal Year 2021 Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

Provides Financial Outlook for 2022 Nuvei reports in U.S. dollars and in accordance with International Financial Reporting Standards (“IFRS”) MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) — Nuvei Corporation (“Nuvei” or the “Company”) (Nasdaq: NVEI) (TSX: NVEI), the global payment technology partner of thriving brands, today reported its financial results for the three months and year ended December 31, 2021. “Our team delivered an excellent quarter in which we exceeded our financial outlook, capping off an exceptional year,” said Nuvei Chair and CEO Philip Fayer. “Our revenue increased 83% for the fourth quarter and 93% for the full year 2021. Total volume increased 127% to $31.5 billion for the quarter, and 121% to $95.6 billion for the year. We have made tremendous progress while investing in our flexible, scalable, modular technology...

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Written by Customer Service on March 8, 2022. Posted in Public Companies.

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has been recognized on Fast Company’s annual list of the World’s Most Innovative Companies for 2022. The list honors businesses that are making the biggest impact in their industries, providing a roadmap for the future of innovation across dynamic sectors of the economy. Myriad placed in the top 10 in the highly competitive Biotech category which recognizes the most innovative scientific laboratories, pharmaceutical, genetics and bio-based health tech companies. Myriad was selected for scientific innovation and tech-enabled capabilities designed...

Ashland’s Responsible Solvers™ program lauds women change agents inside and outside the company

Written by Customer Service on March 8, 2022. Posted in Public Companies.

WILMINGTON, Del., March 08, 2022 (GLOBE NEWSWIRE) — Ashland Global Holdings Inc. (NYSE: ASH) today highlighted critical accomplishments of female employees via the Ashland Women’s International Network (AWIN) and its annual Business Impact Award winners. The celebration, which coincides with International Women’s Day, is a vital component of the company’s Responsible Solvers™ philanthropic program that puts the power of Ashland’s people and products in the hands of its communities to responsibly solve for a better world. Each year, AWIN recognizes women employees for their outstanding and noteworthy contributions to the company’s bottom line. In 2021, seventeen women were selected from among hundreds of nominations across the company, for their positive contributions including: improving efficiencies and cost-savings; solving a...

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Written by Customer Service on March 8, 2022. Posted in Public Companies.

Eyal Rosenthal (photo credit Jim Vetter) Eyal Rosenthal, CEO of Tnuva and Pluristem’s new joint venture. Photographed by Jim Vetter.HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat.Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global venture...

Day: March 8, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals